Nintedanib Accordpharma (Nintedanib Esylate)

Nintedanib is used in fibrotic lung disorders and selected oncologic settings, targeting disease pathways driven by vascular and growth factor signaling.

• Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression.
• Systemic sclerosis‑associated interstitial lung disease: improves pulmonary capacity and delays worsening.
• Non‑small cell lung cancer: used in combination therapy to inhibit tumor angiogenesis and growth.

• Nintedanib inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR 1‑3), fibroblast growth factor receptors (FGFR 1‑3), and platelet‑derived growth factor receptors (PDGFR α/β). By blocking these pathways, it reduces endothelial cell proliferation, fibroblast activation, and extracellular matrix deposition, leading to anti‑angiogenic and antifibrotic effects in lung tissue and tumors.

Nintedanib may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: feeling of sickness, may occur with meals.
• Vomiting: occasional episodes, usually self‑limiting.
• Elevated liver enzymes: mild increases in ALT/AST observed in monitoring.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury requiring discontinuation.
• Bleeding events: gastrointestinal or other hemorrhage, especially with anticoagulants.
• Cardiovascular events: arterial thromboembolism or myocardial infarction.

When prescribing Nintedanib, clinicians should consider several precautionary measures to ensure patient safety.

• Liver function monitoring: assess baseline ALT/AST and repeat regularly.
• Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea.
• Drug interactions: avoid concurrent use with strong CYP3A4 inhibitors unless benefits outweigh risks.
• Bleeding risk: evaluate coagulation status and use caution with anticoagulants.
• Pregnancy and lactation: contraindicated unless potential benefit justifies potential risk; discuss with specialist.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Nintedanib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.
• P-glycoprotein inhibitors (e.g., verapamil): can raise plasma concentrations.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
• Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for signs of bleeding.